Changing the Lives of Patients with
Myotubular and Centronuclear Myopathies (CNM)
Our Focus
We are initially focused on developing treatments for neuromuscular diseases, beginning with myotubular and centronuclear myopathies, or CNM. Our lead product candidate, DYN101, is an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of CNM patients.
People living with CNM disorders are counting on us.

Meet Morice
Morice is his parents’ pride and joy. This two-year-old from the outskirts of Hanover, Germany, presents the classic X-linked form of CNM – a diagnosis that was reached only after a long and difficult journey. But instead of letting this devastating news get the better of them, Morice’s parents made a vow to never stop fighting for their son.